H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio’s rating is based on Sangamo ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $3.18. Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into ...

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

The former chief lobbyist for electric utility Commonwealth Edison has spent the last week telling a federal jury how he bent ...